Mylan Launches First U.S. Generic of Biogen MS Drug Tecfidera
19 Août 2020 - 2:09PM
Dow Jones News
By Colin Kellaher
Mylan N.V. on Wednesday said it has launched its generic version
of Biogen's blockbuster multiple-sclerosis drug Tecfidera in the
U.S. after receiving approval from the Food and Drug
Administration.
Mylan said its dimethyl fumarate delayed-release capsules,
indicated for the treatment of relapsing forms of multiple
sclerosis, are the first generic of any multiple-sclerosis
treatment in an oral solid-dosage form available in the U.S.
Mylan, which has been attacking Biogen's patents in a bid to
launch a generic version of the company's biggest drug, won a major
decision in June when a U.S. district court in West Virginia ruled
that Biogen's patent claims were invalid.
Biogen has vowed to appeal the ruling, and Mylan's launch of its
generic version before final appeals is known as an "at risk" move,
as the company would owe damages for infringing sales if a higher
court restores Biogen's patent.
Tecfidera accounted for roughly 32% of Biogen's second-quarter
revenue of $3.68 billion.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 19, 2020 07:54 ET (11:54 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Mylan NV (NASDAQ:MYL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Mylan NV (NASDAQ:MYL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Mylan NV (NASDAQ): 0 recent articles
Plus d'articles sur Mylan NV